Meanwhile, cash-strapped biotechs have in many cases been forced to leverage relationships with big pharma to address liquidity. Cash is king in a financing environment such as we have observed over the last 18 months, and...more
12/22/2023
/ Borrowers ,
Capital Markets ,
EBITDA ,
Environmental Social & Governance (ESG) ,
EU ,
Financing ,
Healthcare ,
Investment ,
Lenders ,
Life Sciences ,
Secondary Credit Markets ,
Technology Sector ,
Venture Capital
After a year during which uncertainty in the equity markets became the new normal, many stakeholders are wondering whether the disruptions are behind us. A look at key indicators might lead one to say yes. The S&P Loan Index...more
8/4/2021
/ Borrowers ,
Coronavirus/COVID-19 ,
Environmental Social & Governance (ESG) ,
Equity Markets ,
EU ,
European Banking Authority (EBA) ,
Financial Services Industry ,
Financial Stimulus ,
Healthcare ,
Liquidity ,
UK
Despite many similarities, high-yield bonds remain liquid instruments that are freely transferable in accordance with US securities law, whilst leveraged loans are becoming increasingly difficult to trade, particularly during...more
First-Out, Last-Out structures (FOLO), traditionally a key feature of the European mid-market space, seem to have experienced a gradual decline in some markets – whether because of an inadequate return profile or due to a...more
Although companies across many sectors felt the impact of the Coronavirus (COVID-19) pandemic immediately, the true effects and likely impact will not be seen until later this quarter and beyond. Whilst some companies have...more
The Coronavirus (COVID-19) pandemic has not been in play long enough for market participants to properly assess its long-term impact. In the short term, however, the pandemic continues to affect the markets, with many loans...more